Study summary · 2026 · Evidence review

Heart-failure RPM across monitoring approaches: a 2026 review

Pooled results favored HF hospitalization, with no clear all-cause hospitalization benefit and important mortality uncertainty.

Summary by Vironix Health · Source review: November 11, 2026
How we select and interpret evidence

Original publication

Remote Patient Monitoring in Heart Failure: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis

Vicky Muller Ferreira; Victor Ayres Muller

Independent cardiology researcher; Hospital Universitário de Vassouras, Internal Medicine/Clinical Research; Rio de Janeiro, Brazil

Cureus · Online: · Issue: May 2026

Journal version of record, updating the 2026 medRxiv preprint (10.64898/2026.02.25.26347143); counted once. · Full text consulted.

What was studied

Design
Evidence review
Population
Adults with heart failure, predominantly reduced-ejection-fraction or mixed populations
Sample
65 studies reviewed; 59 trials poolable; approximately 23,000 participants reported overall
Intervention
Structured telephone support, non-invasive telemonitoring and invasive/implanted-device monitoring
Comparator
Usual care
Follow-up
Median 6 months; range 2–48 months
Review search cutoff
2026-02-15
Setting
20 countries

Methods

Random-effects meta-analysis with trial sequential analysis and GRADE certainty assessment. Screening used automation with manual adjudication.

Findings

HF hospitalization: RR 0.781 (95% CI 0.710–0.859; low certainty). All-cause mortality: RR 0.911 (0.842–0.985; moderate certainty). All-cause hospitalization: RR 0.959 (0.892–1.031; very low certainty), without a clear reduction.

Limitations

Mortality trim-and-fill sensitivity analysis crossed no effect: RR 0.925 (95% CI 0.851–1.005). The HF hospitalization prediction interval also crossed no effect. Searches omitted Embase/CINAHL; registration followed searching. The pooled trials included no exclusively preserved-ejection-fraction population.

What this means for care delivery

Distinguish monitoring approaches and endpoints. Overlapping reviews are not independent replications; pooled benefits do not guarantee local outcomes.